医学
肌钙蛋白I
心肌梗塞
内科学
肌钙蛋白
观察研究
人口
心脏病学
前瞻性队列研究
流行病学
环境卫生
作者
Jonathan Hinton,Mark Mariathas,Lavinia Gabara,Rick Allan,Zoe Nicholas,Chun Shing Kwok,Sanjay Ramamoorthy,Alison Calver,Simon Corbett,Richard J. Jabbour,Michael Mahmoudi,John Rawlins,Rohit Sirohi,James Wilkinson,Paul Cook,Glen P. Martin,Mamas A. Mamas,Nick Curzen
出处
期刊:Heart
[BMJ]
日期:2023-08-07
卷期号:: heartjnl-322463
标识
DOI:10.1136/heartjnl-2023-322463
摘要
Cardiac troponin (cTn) concentrations above the manufacturer recommended upper limit of normal (ULN) are frequently seen in hospital patients without a clinical presentation consistent with type 1 myocardial infarction, and the significance of this is uncertain. The aim of this study was to assess the relationship between medium-term mortality and cTn concentration in a large consecutive hospital population, regardless of whether there was a clinical indication for performing the test.This prospective observational study included 20 000 consecutive in-hospital and outpatient patients who had a blood test for any reason at a large teaching hospital, and in whom a hs-cTnI assay was measured, regardless of the original clinical indication. Mortality was obtained via NHS Digital.A total of 20 000 patients were included in the analysis and 18 282 of these (91.4%) did not have a clinical indication for cardiac troponin I (cTnI) testing. Overall, 2825 (14.1%) patients died at a median of 809 days. The mortality was significantly higher if the cTnI concentration was above the ULN (45.3% vs 12.3% p<0.001 log rank). Multivariable Cox analysis demonstrated that the log10 cTnI concentration was independently associated with mortality (HR 1.76 (95% CI 1.65 to 1.88)). Landmark analysis, excluding deaths within 30 days, showed the relationship between cTnI concentration and mortality persisted.In a large, unselected hospital population, in 91.4% of whom there was no clinical indication for testing, cTnI concentration was independently associated with medium-term cardiovascular and non-cardiovascular mortality in the statistical model tested.
科研通智能强力驱动
Strongly Powered by AbleSci AI